top of page

PrecisionPoint™ Transperineal Access System - revolutionising the methodology for obtaining prostate biopsies

BXTAccelyon are the sole distributor, outside North America, for the PrecisionPoint™ single use device, that enables transperineal biopsies under local anaesthetic.


Early detection of prostate cancer is proven to widen the available treatment options to patients, improving outcomes whilst reducing potential adverse side-affects.


The PrecisionPoint™ Transperineal Access System revolutionises the methodology for obtaining prostate biopsies. This medical system takes full advantage of the transperineal path to more thoroughly sample all regions of the prostate including those difficult to access with the transrectal approach. PrecisionPoint™ provides improved accuracy and convenience, enabling surgeons to achieve savings in both costs and time. The transperineal biopsy technique is free hand, therefore the practitioner can easily target the desired locations with certainty and through a single puncture of the skin.

The benefits


  • Convenient free hand, easy to learn

  • Decreases risk of infections over the transrectal approach

  • Allows systematic template-style sampling without the need for a template or stepper and stabilizer unit

  • Higher cancer detection rate than TRUS

  • Performed under local anesthesia, so the procedure can be undertaken in an outpatient clinic

Transrectal vs. Transperineal

By passing the biopsy needle through the perineum instead of the rectum, the risks associated with the transrectal approach are avoided. The practitioner is not restricted to biopsy locations dictated by a grid configuration, since the technique is freehand. The practitioner can freely manoeuvre the ultrasound probe to align the access needle to target the desired locations with certainty for targeted and systematic biopsies.

This low cost disposable device represents a safer and more accurate method for urologists to detect potential incidents of prostate cancer at an earlier stage of progression, through its ability to systematically allow access to the whole gland.

Transperineal Prostate Biopsy Explained

For more information, please contact:

John Alden

Commercial Director, Northern Europe

Tel: +44 (0) 7881 029140

Nicola Leavold

Sales Director, Australasia

Tel: +61 409 458 852

Jos Groeskamp

Tel: 0031 (0) 646808058

bottom of page